KOL Views: How much interest is there in prescribing Teva’s AirDuo rather than branded or (eventually) generic Advair?

Teva is attempting an end-around on regulatory barriers holding back substitutable generic versions of GlaxoSmithKline’s Advair (fluticasone/salmeterol) by launching an authorised generic of AirDuo, a newly approved but non-substitutable equivalent of the respiratory drug, which the Israeli company will sell for a bargain-basement price in hopes of gaining traction from stakeholders. (See ViewPoints: A generic by any other name – will stakeholders buy in on Teva’s kinda sorta generic equivalent to Advair?)

To provide FirstWord readers with a more granular look at what physicians think of AirDuo and how it stacks up against branded Advair and (eventually) AB-rated generics, we are hosting an expert call with a key opinion leader this week.

Key topics that will be discussed during the call include, among other things… level of anticipation for generic equivalents of Advair, comfort level with prescribing branded and/or authorised generic versions of AirDuo, are there certain subgroups that might be most appropriate for using AirDuo, how much cheaper would AirDuo need to be to use it instead of a AB-rated generic equivalent of Advair, what asthma/COPD drugs would you expect to use less of with the availability of AirDuo for $90?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the brewing competition among Advair and its substitutable generic and non-substitutable generic-like equivalents.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.